'Armored' CAR T Cells Show Early Promise in Relapsed B-Cell ALL

(MedPage Today) — At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting “armored” CAR T-cell therapy that is designed to enhance persistence and antileukemic…

Source link : https://www.medpagetoday.com/meetingcoverage/ashvideopearlsall/119164

Author :

Publish date : 2025-12-23 17:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

‘Armored’ CAR T Cells Show Early Promise in Relapsed B-Cell ALL

FDA Approves First Oral Medication for Iron Deficiency in Kids

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

Related Posts

The Midterms Are Coming. Vaccines May Play a Role.

Six-Monthly HIV Prevention Injection Cleared by MHRA

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

FDA Approves First Oral Medication for Iron Deficiency in Kids

Blood-Based Immune Markers May Predict Response to Preoperative Therapy in TNBC

Reassuring Findings for Use of Common Sleep Medications in Pregnancy

The Midterms Are Coming. Vaccines May Play a Role.

Six-Monthly HIV Prevention Injection Cleared by MHRA

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

‘Armored’ CAR T Cells Show Early Promise in Relapsed B-Cell ALL

FDA Approves First Oral Medication for Iron Deficiency in Kids

Blood-Based Immune Markers May Predict Response to Preoperative Therapy in TNBC

Reassuring Findings for Use of Common Sleep Medications in Pregnancy

Study Highlights Issues in Care of Latine Patients With HC

Categories

Archives